"Opening Ceremony of the International Society for Personalized Metabolic Oncology"
Date: April 5–6, 2025
Location: Kuala Lumpur, Malaysia
Event: Opening Ceremony of the International Society for Personalized Metabolic Oncology (ISPMO)
Speaker: Dr. Jervin (President, ISPMO)
RGCC was honored to participate in a landmark international conference held in Kuala Lumpur, marking the official launch of the International Society for Personalized Metabolic Oncology (ISPMO).
The two-day event brought together approximately 75 medical and integrative medicine practitioners from across Southeast Asia for in-depth discussions on the latest clinical advancements in personalized metabolic oncology.
Hosted in the heart of Malaysia’s capital, the conference featured a series of keynote presentations and expert-led workshops aimed at sharing scientific knowledge and clinical best practices in the rapidly evolving field of integrative cancer care.
Dr. Ioannis Papasotiriou, Director and CEO of RGCC International, joined the distinguished lineup of speakers, which also included Dr. John Soo, Dr. Sarah Khong, and a panel of seasoned integrative physicians and oncologists from across the region.
Date: November 2024
Event: Memorandum of Understanding with the Indonesian Society of Surgical Oncology
Under the leadership of Dr. Jervin, RGCC SEA accompanied founder Dr. Ioannis in a visit to Universitas Hasanuddin (UNHAS) in Indonesia.
The Faculty of Medicine at Universitas Hasanuddin, established in 1956, is the oldest and largest medical school in Eastern Indonesia.
Date: November 2024
Participants: RGCC members and the Indonesian Society of Surgical Oncology (PERABOI)
Research Project:
"Clinical Application of Circulating Tumor Cell (CTC) Profiling in Monitoring Pathological Response and Distant Metastasis-Free Survival in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy"
This study aims to explore the potential of CTC analysis as a predictive tool for pathological and clinical outcomes in breast cancer patients undergoing neoadjuvant chemotherapy.
The research is expected to provide valuable insights into how CTC profiling can help monitor tumor response and survival outcomes, potentially transforming the clinical management of breast cancer.
